| Schedule of segment reporting information |
| Schedule of segment reporting information |
|
|
|
|
|
|
|
|
| |
|
Three Months Ended
March 31, |
|
| |
|
2026 |
|
|
2025 |
|
| Total revenues |
|
|
|
|
|
|
|
|
| US |
|
$ |
14,950 |
|
|
$ |
20,443 |
|
| International |
|
|
- |
|
|
|
20,572 |
|
| Total Revenue |
|
|
14,950 |
|
|
|
41,015 |
|
| Less: |
|
|
|
|
|
|
|
|
| Cost of revenues (excluding amortization and depreciation) |
|
|
1,817 |
|
|
|
13,558 |
|
| Research and development expense (excluding share-based compensation expense): |
|
|
|
|
|
|
|
|
| Clinical trials |
|
|
198,445 |
|
|
|
61,352 |
|
| EDC Build |
|
|
55,800 |
|
|
|
18,050 |
|
| Halo project |
|
|
88,767 |
|
|
|
298,037 |
|
| SYNC project |
|
|
- |
|
|
|
23,713 |
|
| Other research and development(a) |
|
|
3,370 |
|
|
|
5,136 |
|
| General and administrative and
salaries and benefits expense (excluding stock based compensation, depreciation and amortization expense) |
|
|
801,904 |
|
|
|
622,948 |
|
| Depreciation |
|
|
4,106 |
|
|
|
- |
|
| Amortization |
|
|
6,736 |
|
|
|
4,786 |
|
| Stock based compensation |
|
|
478,611 |
|
|
|
636,844 |
|
| Professional fees |
|
|
495,296 |
|
|
|
367,816 |
|
| Interest income, net |
|
|
(34 |
) |
|
|
(1,103 |
) |
| Equity in net income from equity method investees |
|
|
- |
|
|
|
1,048 |
|
| Other income |
|
|
(23,031 |
) |
|
|
(22,833 |
) |
| Segment net loss |
|
|
(2,096,837 |
) |
|
|
(1,988,337 |
) |
| |
|
|
|
|
|
|
|
|
| Reconciliation of net loss |
|
|
|
|
|
|
|
|
| Adjustments and reconciling items |
|
|
- |
|
|
|
- |
|
| Consolidated net loss |
|
$ |
(2,096,837 |
) |
|
$ |
(1,988,337 |
) |
| (a) |
Other research and development expenses primarily consist of facilities charges, third party consultant costs, costs related to other product candidates, and other unallocated costs. |
|